Immunogenicity, Safety, Tolerability of a Plant-made H5 VLP Influenza Vaccine.
Phase of Trial: Phase II
Latest Information Update: 28 Sep 2015
At a glance
- Drugs Influenza A virus vaccine-H5N1 (Primary) ; Aluminium hydroxide; Glycopyranosyl lipid adjuvant
- Indications Influenza A virus H5N1 subtype
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Medicago
- 24 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 25 Nov 2013 New source identified and integrated: ClinicalTrials.gov record.
- 20 Jun 2013 Interim data expected in the second half of 2013, according to a Medicago media release.